Skip to main content

Advertisement

Table 1 Patient information and dosimetric parameters

From: Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer

Characters Histology/stage Patients (n) Median Percentage/range
Age    56 years 20–78 years
Histology Serous 85   56.7%
Endometrioid 41   27.3%
Mucinous 9   6.0%
Clear cell 6   4.0%
Mixed type 9   6.0%
FIGO stage I–II 28   18.7%
III–IV 122   81.3%
Histological grade G1 38   25.3%
G2 67   44.7%
G3 45   30.0%
Tumor residual size 0 cm 42   28.0%
≤ 1 cm 71   47.3%
> 1 cm 37   24.7%
Tumor size ≤ 10 cm 67   44.7%
> 10 cm 83   55.3%
Platinum-based Cisplatin-based 31   20.7%
Carboplatin-based 119   79.3%
Follow-up time   150 36.5 months 2–86 months
  1. FIGO International Federation of Gynecology and Obstetrics